Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Harbin Gloria in $170 Million Deal to Acquire Huatuo Medical Science

publication date: Feb 21, 2014
Harbin Gloria Pharma acquired Shanghai Huatuo Medical Science through a series of purchases with at least 75 shareholders. All together, Gloria paid 993.1 million RMB for a 90.9% stake in Huatuo, though it owns 98.9% of the company (it did not disclose the price on an 8% purchase). Huatuo has committed to producing profits of at least 106 million RMB in 2014. Gloria said the purchase price works out to a price/earnings ratio of 9.6, implying a purchase price of just over 1 billion RMB ($170 million). More details....

Stock Symbol: (SHE: 002437)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital